Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

[1]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[3]  I Royston,et al.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. , 1997, Blood.

[4]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[5]  J. Gribben,et al.  Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. , 1994, Blood.

[6]  Ina Ruck,et al.  USA , 1969, The Lancet.

[7]  R. Warnke,et al.  Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. , 1988, The New England journal of medicine.

[8]  S. Kon,et al.  Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. , 1982, The New England journal of medicine.

[9]  B. Wilkes,et al.  The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. , 1988, Blood.

[10]  J. Brown,et al.  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.

[11]  W. Velasquez,et al.  The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. , 1987, Blood.

[12]  F. Appelbaum,et al.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.

[13]  A. Forsgren,et al.  Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes , 1986, European journal of immunology.

[14]  E. Clark,et al.  The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.

[15]  A. Freedman,et al.  The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. , 1985, Journal of immunology.

[16]  E. Clark,et al.  Role of the Bp35 cell surface polypeptide in human B-cell activation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. R. Howe,et al.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. , 1982, The New England journal of medicine.

[18]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[19]  K. Abromeit.  Music Received , 2023, Notes.